RXRXRecursion Pharmaceuticals, Inc.

1. Sep 21, 2026Recursion Pharmaceuticals, Inc. (the "Company") and Tempus AI, Inc. ("Tempus"), acknowledging the value of (i) Tempus’s library of multimodal data and (ii) Recursion’s proprietary foundational RNA sequencing model (the "TxFM Model"), have entered into the following agreements: Amendment to Tempus Master Agreement On …Material agreement entered · Form 8-K
2. Aug 5, 2026Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program.Earnings release · press release
3. May 6, 2026Recursion Reports First Quarter Financial Results and Provides Business Update.Earnings release · press release
4. Apr 30, 2026On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will …Director or officer change · Form 8-K
5. Mar 25, 2026On March 25, 2026, Recursion Pharmaceuticals, Inc. (the “Company”) announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026, as David Mauro, M.D., Ph.D. transitions out of the role.Director or officer change · Form 8-K
6. Feb 25, 2026Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
7. Dec 8, 2025On December 8, 2025, Recursion Pharmaceuticals, Inc. (“Recursion” or the “Company”) issued a press release announcing Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP)Other event · Form 8-K
8. Nov 26, 2025On November 26, 2025, Recursion Pharmaceuticals, Inc. (“Recursion”) filed a prospectus supplement dated November 26, 2025 (the “Tempus Prospectus Supplement”) and an accompanying base prospectus, which are part of Recursion’s automatic “shelf” Registration Statement on Form S-3ASR (File No. 333-284878) (the …Other event · Form 8-K
9. Nov 5, 2025On November 4, 2025, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) appointed Najat Khan, Ph.D., the Company’s Chief Research and Development Officer and Chief Commercial Officer, as the Company’s Chief Executive Officer and President, and appointed Christopher Gibson, Ph.D. …Earnings release · Form 8-K
10. Oct 29, 2025On October 29, 2025, Recursion Pharmaceuticals, Inc. (the “Company” or “Recursion”) announced the exercise of the option by Roche (as defined below) for a Microglia Map—a first-of-its-kind whole genome map of the brain’s immune cells—generated by Recursion under the Collaboration and License Agreement with Genentech …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.